View Item 

Show simple item record

Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitis

dc.contributor.authorStidham, R. W.en_US
dc.contributor.authorLee, T. C. H.en_US
dc.contributor.authorHiggins, P. D. R.en_US
dc.contributor.authorDeshpande, A. R.en_US
dc.contributor.authorSussman, D. A.en_US
dc.contributor.authorSingal, A. G.en_US
dc.contributor.authorElmunzer, B. J.en_US
dc.contributor.authorSaini, S. D.en_US
dc.contributor.authorVijan, S.en_US
dc.contributor.authorWaljee, A. K.en_US
dc.date.accessioned2014-03-05T18:19:14Z
dc.date.available2015-06-01T15:48:45Zen_US
dc.date.issued2014-04en_US
dc.identifier.citationStidham, R. W.; Lee, T. C. H.; Higgins, P. D. R.; Deshpande, A. R.; Sussman, D. A.; Singal, A. G.; Elmunzer, B. J.; Saini, S. D.; Vijan, S.; Waljee, A. K. (2014). "Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitis." Alimentary Pharmacology & Therapeutics 39(7): 660-671.en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106149
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherAgency for Healthcare Research and Quality (US)en_US
dc.titleSystematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106149/1/apt12644.pdf
dc.identifier.doi10.1111/apt.12644en_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceDu Pan SM, Dehler S, Ciurea A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti‐tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009; 61: 560 – 8.en_US
dc.identifier.citedreferenceHiggins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003; 327: 557 – 60.en_US
dc.identifier.citedreferenceGeMTC: network meta‐analysis software. Available at: http://drugis.org/gemtc.en_US
dc.identifier.citedreferenceThorlund K, Mills EJ. Sample size and power considerations in network meta‐analysis. Syst Rev 2012; 1: 41.en_US
dc.identifier.citedreferenceKaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131: 308 – 16.en_US
dc.identifier.citedreferenceNesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti‐tumor necrosis factor α agents. Inflamm Bowel Dis 2007; 13: 1323 – 32.en_US
dc.identifier.citedreferenceVos ACW, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW. Anti‐tumor necrosis factor‐ α antibodies induce regulatory macrophages in an Fc region‐dependent manner. Gastroenterology 2011; 140: 221 – 30.en_US
dc.identifier.citedreferenceKestens C, van Oijen MG, Mulder CL, et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti‐tumor necrosis factor‐alpha agents. Clin Gastroenterol Hepatol 2013; 11: 826 – 31.en_US
dc.identifier.citedreferenceOsterman MT, Haynes K, Delzell E, et al. Comparative effectiveness of infliximab and adalimumab for Crohn's Disease. Clin Gastroenterol Hepatol 2013; doi: 10.1016/j.cgh.2013.06.010 [Epub ahead of print].en_US
dc.identifier.citedreferenceSussman DA, Kubiliun N, Mulani PM, et al. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis 2012; 18: 2043 – 55.en_US
dc.identifier.citedreferenceChoi GKH, Collins SDE, Greer DP, et al. Costs of adalimumab versus infliximab as first‐line biological therapy for luminal Crohn's disease. J Crohns Colitis 2013; doi: 10.1016/j.crohns.2013.09.017 [Epub ahead of print].en_US
dc.identifier.citedreferenceSingh S, Nagpal SJ, Murad MH, et al. Inflammatory Bowel disease is associated with an increased risk of melanoma: a systematic review and meta‐analysis. Clinical Gastroenterol Hepatol 2014; 12: 210 – 8.en_US
dc.identifier.citedreferenceFord AC, Peyrin‐Biroulet L. Opportunistic infections with anti‐tumor necrosis factor‐alpha therapy in inflammatory bowel disease: meta‐analysis of randomized controlled trials. Am J Gastroenterol 2013; 108: 1268 – 76.en_US
dc.identifier.citedreferenceSiegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti‐tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta‐analysis. Clinical Gastroenterol Hepatol 2009; 7: 874 – 81.en_US
dc.identifier.citedreferenceWilliams CJ, Peyrin‐Biroulet L, Ford AC. Systematic review with meta‐analysis: malignancies with anti‐tumour necrosis factor‐alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014; 39: 447 – 458.en_US
dc.identifier.citedreferenceChilton F, Collett RA. Treatment choices, preferences and decision‐making by patients with rheumatoid arthritis. Musculoskeletal Care 2008; 6: 1 – 14.en_US
dc.identifier.citedreferenceScarpato S, Antivalle M, Favalli EG, et al. Patient preferences in the choice of anti‐TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) 2010; 49: 289 – 94.en_US
dc.identifier.citedreferenceRenna S, Camma C, Modesto I, et al. Meta‐analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2008; 135: 1500 – 9.en_US
dc.identifier.citedreferenceRangwalla SC, Waljee AK, Higgins PDR. Voting with their feet (VWF) endpoint: a meta‐analysis of an alternative endpoint in clinical trials, using 5‐ASA induction studies in ulcerative colitis. Inflamm Bowel Dis 2009; 15: 422 – 8.en_US
dc.identifier.citedreferenceGlenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9: 1 – 134.en_US
dc.identifier.citedreferenceSong F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009; 338: b1147.en_US
dc.identifier.citedreferenceColeman CI, Phung O, Cappelleri JC, et al. Use of Mixed Treatment Comparisons in Systematic Reviews [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US), 2012.en_US
dc.identifier.citedreferenceThorlund K, Druyts E, Aviña‐Zubieta JA, Wu P, Mills EJ. Why the findings of published multiple treatment comparison meta‐analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Ann Rheum Dis 2013; 72: 1524 – 35.en_US
dc.identifier.citedreferenceAHRQ. Methods Research Report ‐ Findings of Bayesian Mixed Treatment Comparison Meta‐Analyses: Comparison and Exploration Using Real‐World Trial Data and Simulation. 2013: 1–143.en_US
dc.identifier.citedreferenceReinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13: 1135 – 40.en_US
dc.identifier.citedreferenceVogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health‐related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2009; 2: 101 – 9.en_US
dc.identifier.citedreferenceCohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010; 31: 693 – 707.en_US
dc.identifier.citedreferenceBassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471 – 8.en_US
dc.identifier.citedreferenceReinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780 – 7.en_US
dc.identifier.citedreferenceSandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate‐to‐severe ulcerative colitis. Gastroenterology 2012; 142: 257 – 65.e1–3.en_US
dc.identifier.citedreferenceSandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate‐to‐severe ulcerative colitis. Gastroenterology 2014; 146: 85 – 95.en_US
dc.identifier.citedreferenceProbert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 998 – 1002.en_US
dc.identifier.citedreferenceRutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462 – 76.en_US
dc.identifier.citedreferenceSandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate‐to‐severe ulcerative colitis. Gastroenterology 2014; 146: 96 – 109. e1.en_US
dc.identifier.citedreferenceVan Assche G, Vermeire S, Ballet V, et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2012; 61: 229 – 34.en_US
dc.identifier.citedreferenceLiberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.en_US
dc.identifier.citedreferenceSchroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5‐aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625 – 9.en_US
dc.identifier.citedreferenceSchoenfeld P, Cook D, Hamilton F, Laine L, Morgan D, Peterson W. An evidence‐based approach to gastroenterology therapy. Evidence‐Based Gastroenterology Steering Group. Gastroenterology 1998; 114: 1318 – 25.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt12644.pdf
Size:
296.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.